Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001193805-16-004039
Filing Date
2016-09-30
Accepted
2016-09-29 19:54:55
Documents
1
Group Members
DEERFIELD INTERNATIONAL MASTER FUND, L.P.DEERFIELD MANAGEMENT COMPANY, L.P.DEERFIELD MGMT, L.P.DEERFIELD PARTNERS, L.P.DEERFIELD SPECIAL SITUATIONS FUND, L.P.

Document Format Files

Seq Description Document Type Size
1 e615451_sc13ga-vanda.htm SC 13G/A 386214
  Complete submission text file 0001193805-16-004039.txt   387742
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Subject) CIK: 0001347178 (see all company filings)

EIN.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-82196 | Film No.: 161911087
SIC: 2834 Pharmaceutical Preparations

Mailing Address 780 THIRD AVENUE 37TH FLOOR NEW YORK NY 10017
Business Address
Flynn James E (Filed by) CIK: 0001352546 (see all company filings)

Type: SC 13G/A